Changes in Hong Kong stocks | True Health (02697) rose more than 6% and General Technology and Liaoning Pharmaceutical jointly explore the minimally invasive cancer diagnosis and treatment market in Northeast China and accelerate the formation of a closed commercial loop

The Zhitong Finance App learned that True Health Care (02697) rose by more than 6%. As of press release, it had risen 5.09% to HK$692, with a turnover of HK$11.297 million.

According to the news, on August 25, True Health Medical issued a voluntary announcement announcing that it had signed a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical in Shenyang on August 22. Based in the three northeastern provinces, the two sides will cooperate on the construction of minimally invasive cancer diagnosis and treatment systems, equipment compliance, and specialist capacity enhancement, and adopt models such as joint specialist construction, equipment technical services, and operational leasing to promote the standardization and implementation of minimally invasive cancer intervention technology. From the Guangdong-Hong Kong-Macao Greater Bay Area to the old industrial base in Northeast China, from the Hengqin Guangdong-Macao Deep Cooperation Zone to the national layout of True Health Care, a provincial platform for central enterprises, we are completing an in-depth strategic advance spanning thousands of kilometers.

It is worth mentioning that as of June 1, 2026, the company's products have entered nearly 100 medical institutions across the country, with a cumulative total of more than 7,200 surgeries, with a technical success rate of 100%; 6 devices were delivered in 2025, and the revenue increased from 1.791 million yuan in 2024 to 12.178 million yuan, an increase of about 5.8 times over the previous year, with a gross margin of 76.3%. From “obtaining a license” to “installing” to re-purchasing consumables, a closed loop in the real health care business is being formed at an accelerated pace.